Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Evolving Treatment Landscape in Metastatic Colorectal Cancer

July 21st 2023

Tanios S. Bekaii-Saab, MD, discusses recent clinical trials and provides insights on the evolving metastatic colorectal cancer treatment landscape.

Dr Andre on the SOLSTICE Trial in mCRC

July 21st 2023

Thierry Andre, MD, discusses the efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer and the safety profiles of the 2 arms of the phase 3 SOLSTICE trial.

Dr Desai on the Evolution of Divarasib in KRAS G12C-mutated CRC

July 19th 2023

Jayesh Desai, MBBS, FRACP, discusses the evolution of divarasib, highlighting the rationale for combining the KRAS G12C inhibitor with cetuximab in patients with advanced colorectal cancer harboring KRAS G12C mutations in a phase 1b study.

Examining the Promise of Multicancer Early Detection Tests: Takeaways From the ECLIPSE Trial

July 19th 2023

In this sixth episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss important takeaways from the ECLIPSE study (NCT04136002), which evaluated a cell-free DNA blood-based test for colorectal cancer in an average-risk population.

IMX-110 Plus Tislelizumab Leads to Tumor Shrinkage in Heavily Pretreated mCRC

July 19th 2023

Treatment with the combination of the tissue-specific therapeutic IMX-110 and the anti–PD-1 antibody tislelizumab led to tumor shrinkage in heavily pretreated patients with metastatic colorectal cancer.

HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With T-DXd

July 19th 2023

Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.

HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With Tucatinib

July 19th 2023

A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.

Dr Taieb on the Safety Proline of TAS-102/Bevacizumab in Refractory mCRC

July 18th 2023

Julien Taieb, MD, PhD, discusses the safety profile associated with trifluridine/tipiracil with bevacizumab in refractory metastatic colorectal cancer.

HER2 as a Biomarker in Metastatic Colorectal Cancer

July 14th 2023

An expert on colorectal cancer discusses the relationship between HER2 status and treatment selection and response.

Overview of Metastatic Colorectal Cancer: Presentation and Molecular Testing

July 14th 2023

Tanios S. Bekaii-Saab, MD, gives an overview of the presentation trends and molecular testing practices for metastatic colorectal cancer.

Dr Abushahin on Biomarker Testing in mCRC

July 13th 2023

Laith Abushahin, MD, discusses the evolution of targeted therapy for patients with metastatic colorectal cancer and the importance of biomarker testing in this patient population.

DKN-01 Plus Bevacizumab/Chemotherapy Advances to Part B in DeFianCe Trial in Advanced CRC

July 13th 2023

Leap Therapeutics has launched the randomized, controlled part B of the phase 2 DeFianCe trial, which will evaluate DKN-01 in combination with bevacizumab and chemotherapy as second-line therapy in patients with advanced colorectal cancer.

Assessing HER2 Expression in Metastatic Colorectal Cancer

July 12th 2023

Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.

Novel Combination Strategies in BRAF-Mutant Metastatic Colorectal Cancer

July 12th 2023

Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.

Botensilimab Plus Balstilimab Provides OS Benefit in Heavily Pretreated MSS mCRC

July 5th 2023

The combination of botensilimab and balstilimab elicited durable responses and provided overall survival benefits in patients with microsatellite stable metastatic colorectal cancer that is resistant to chemotherapy and/or immunotherapy.

TAS-102/Bevacizumab Prolongs OS, PFS in Patients With mCRC and Maintained ECOG PS of 0 or 1

July 5th 2023

Julien Taieb, MD, discusses the importance of combining fluoropyrimidines with bevacizumab, key findings from the SUNLIGHT trial and the post-hoc analysis, and how these results may shake up the colorectal cancer treatment paradigm.

Dr Schrag on Neoadjuvant Chemotherapy and Selective Chemoradiation in Locally Advanced Rectal Cancer

July 5th 2023

Deb Schrag, MD, MPH, discusses findings from the phase 2/3 PROSPECT trial in patients with rectal cancer.

Metastatic Colorectal Cancer: Tumor Sidedness and EGFR-Targeted Therapy

July 5th 2023

Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.

BRAF V600E–Mutant Metastatic Colorectal Cancer: BREAKWATER Study

July 5th 2023

Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.

Treatment Options for BRAF V600E–Mutant Metastatic Colorectal Cancer

June 28th 2023

Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.